SEC Filing
07/04/2025 21:24
April 7 (Reuters) - Atossa Therapeutics Inc ATOS.O: ATOSSA THERAPEUTICS INC - INTAS PHARMACEUTICALS FILES PETITION FOR POST GRANT REVIEW AGAINST CO- SEC FILING ATOSSA THERAPEUTICS INC - INTAS PHARMACEUTICALS FILES PETITION FOR INTER PARTES REVIEW AGAINST CO ATOSSA THERAPEUTICS INC - TO CONTEST PGR AND IPR PETITIONS - SEC FILING Source text: [ID:n0000950170-25-051575] Further company coverage: ATOS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atossa Therapeutics
See all newsAtossa Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Atossa Therapeutics Q3 net loss narrows as clinical trial expenses decline
Brief: Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation In Potential Priority Review Voucher Value
US RESEARCH ROUNDUP-Amrize, Dexcom, Lennar
Atossa Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary